DarioHealth Corp.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 2, 2023 and accepted by EDGAR at Nov 2, 2023, 06:05 ET.
Management's discussion and analysis
As filed, 30,523 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
The following financial data in this narrative are expressed in thousands, except for stock and stock data or as otherwise noted.
We are revolutionizing how people with chronic conditions manage their health through the innovation of a new category of digital health: Digital Therapeutics as a Service (“DTaaS”). We believe that our innovative approach to digital therapeutics disrupts the traditional provider-centered system of healthcare delivery by offering user-centric care that is continuous, customized supportive of better overall health. Our solutions combine the power of technologies and behavior science to make better health accessible, affordable, and easy for all by solving for what people need, when and where they want it, with hyper-personalized care that is always connected – to services, devices, and people – and delivered continuously. Our solutions are proven to drive savings for health plans and employers by improving the health of their populations.
We began as a direct-to-consumer digital therapeutics company, solving first for the problem of how to engage users and support behavior change to improve clinical outcomes in diabetes. Beginning in 2020, we enacted a strategic shift to transform the business model by deploying a business-to-business-to-consumer (“B2B2C”) approach, leveraging the strengths of our consumer solution platform to enable commercial growth opportunities in traditional health business channels by selling to health plans and employers.
At the same time, we expanded from a single-condition platform to a multi-condition platform, creating a robust suite of solutions to address the five most commonly co-occurring, behaviorally driven, and expensive chronic conditions, which are also representative of some of the most sought-after digital health solutions: diabetes, hypertension, pre-diabetes/weight management, musculoskeletal and behavioral health. After building weight loss and hypertension management into the legacy diabetes platform, we made three acquisitions in order to expand into musculoskeletal (MSK) and behavioral health (BH). In that regard, we acquired Upright, PsyInnovations and Physimax Technology assets to expand into the fields of MSK and BH. Our approach to integrating all solutions into one digital therapeutics platform follows the “best-of-suite” offering design principal which provides the user one place to monitor all identified chronic conditions and to deliver a seamless user experience for commonly co-occurring chronic conditions.
These two shifts led to the rapid expansion of our B2B2C business over the last two years and positioned us for success in commercial markets. We continue to achieve key benchmarks as we rapidly scale our B2B2C model, including more than 100 total signed contracts to date and the shift in our commercial pipeline where more than 50% of the contracts signed in the second half of 2022 are for multi-chronic solutions. We believe we have a unique and defensible position in the market thanks to our unique solution origin in consumer markets.
We continue to generate a significant number of clinical publications. In that regard, we have published 44 real world data studies with total of 10 and 7 generated in 2022 and 2023, respectively, and several more already planned for 2023.
We believe that we are proving the value of our solutions as enterprise business sales continue to grow. With more than 100 signed contracts to date, we have solid evidence on the key differentiators that lead to new business opportunities: a consumer-friendly approach that drives engagement; deep integration capabilities; and best-in-class clinical outcomes.
Recent Developments
Employer Contracts
In August 2023, we announced the expansion of our agreement with a large regional health plan to deliver highly personalized digital health solutions to plan members living with diabetes. The launch for this large regional health plan is anticipated to be in the first quarter of 2024.
In August 2023, we announced a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology, to offer integrated digital health solutions to more than five million consumers.
In October 2023, we announced a new strategic partnership with a top five national employee benefits consulting firm to become the preferred digital health and chronic condition solution partner for its national employer clients.
Presentation of New Studies
In August 2023, we announced new research presented at the ADCES23 Annual Conference held in Houston, Texas. The new research demonstrated our ability to sustainably improve health outcomes for users with diabetes over a two-year period.
In September 2023, we announced new research published in the Journal of Medical Internet Research (JMIR) demonstrating the impact of coaching and breathing exercises as part of our digital behavioral health program alongside coaching and breathing exercises for members living with depression or anxiety.
In October 2023, we announced new research presented by Sanofi at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus, demonstrating a 36% reduction in 30-day hospital readmissions for our users compared to non-users living with type 2 diabetes.
Launch of Apple iPhone 15 Accessible Smart Blood Glucose Meter
In November 2023, we announced the launch of a new smart blood sugar meter for Apple iPhone 15 users to support ongoing engagement with new and existing members.
Results of Operations
Comparison of the three and nine months ended September 30, 2023, and September 30, 2022 (dollar amounts in thousands)
Revenues
Revenues for the three and nine months ended September 30, 2023, amounted to $3,518 and $16,736 respectively, compared to revenues of $6,605 and $20,847 during the three and nine months ended September 30, 2022, representing a decrease of 46.7% and 19.7%, respectively. The decrease in revenues for the three months ended September 30, 2023, compared to the three months ended September 30, 2022, resulted mainly from a reduction in revenue relating to data access and development services derived from the Company’s strategic partnerships that are included in revenues from providing services. The decrease in revenues for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, resulted mainly from the intended reduction in revenues from consumer hardware sales and a reduction in revenue relating to data access and development services derived from the Company’s strategic partners that are included in revenues from providing services.
Cost of Revenues
During the three and nine months ended September 30, 2023, we recorded cost of revenues in the amount of $2,908 and $10,884, respectively, compared to costs related to revenues of $4,805 and $13,924 during the three and nine months ended September 30, 2022, representing a decrease of 39.5% and 21.8%, respectively. The decrease in cost of revenues in the three months ended September 30, 2023, compared to the three months ended September 30, 2022, was mainly due to lower cost of revenues from our services channel due to a postponement of certain projects caused by our strategic partner. The decrease in cost of revenues in the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, was mainly due to lower cost of revenues from our consumer hardware channel, resulting mainly from an intended reduction in revenues from our consumer hardware channel.
Cost of revenues consist mainly of cost of device production, employees’ salaries and related overhead costs, depreciation of production line and related cost of equipment used in production, amortization of technologies, hosting costs, shipping and handling costs and inventory write-downs.
Gross Profit
Gross profit for the three and nine months ended September 30, 2023, amounted to $610 (17.3% of revenues) and $5,852 (35% of revenues), respectively, compared to $1,800 (27.3% of revenues) and $6,923 (33.2% of revenues) during the three and nine months ended September 30, 2022. The decrease in gross profit as a percentage of revenues for the three months ended September 30, 2023, compared to the three months ended September 30, 2022, is due to the decrease in gross profit derived from the sale of services partially offset by an increase in the gross profit generated from consumer hardware. The increase in gross profit as a percentage of revenues for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, is due to the increase in the gross profit generated from consumer hardware revenues partially offset by a decrease in gross profit derived from revenues derived from services. Gross profit for the three and nine months ended September 30, 2023, excluding amortization of acquired technology were $1,716 (48.8% of revenues) and $9,133 (54.6% of revenues) compared to $2,905 (44% of revenues) and $10,054 (48.2% of revenues) during the three and nine months ended September 30, 2022.
Research and Development Expenses
Our research and development expenses increased by $862, or 17.9%, to $5,665 for the three months ended September 30, 2023, compared to $4,803 for the three months ended September 30, 2022, and increased by $1,185, or 8%, to $16,052 for the nine months ended September 30, 2023, compared to $14,867 for the nine months ended September 30, 2022. The increase in research and development expenses for the three months ended September 30, 2023 compared to the three months ended September 30 2022 was mainly a result of a reduction in the allocation of payroll expenses related to development services provided under our strategic agreements to the cost of revenues, partially offset by a reduction in subcontractors and consulting expenses. The increase in research and development expenses for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022, was mainly due to an increase in payroll expenses, share-based compensation expenses, a reduction in the allocation of payroll expenses related to development services provided under our strategic agreements to the cost of revenues and other research and development expenses, partially offset by a reduction in subcontractors and consulting expenses. Our research and development expenses, excluding stock-based compensation and depreciation, for the three and nine months ended September 30, 2023, were $4,417 and $12,282 compared to $3,625 and $11,620 for the three and nine months ended September 30, 2022, an increase of $792 and $6,624, respectively.
Research and development expenses consist mainly of employees’ salaries and related overhead costs involved in research and development activities, expenses related to: (i) our solutions including our Dario Smart Diabetes Management Solution, our engagement platform, Dario Move solution and our digital behavioral health solution, (ii) labor contractors and engineering expenses, (iii) depreciation and maintenance fees related to equipment and software tools used in research and development, (iv) clinical trials performed in the United States to satisfy the FDA product approval requirements and (v) facilities expenses associated with and allocated to research and development activities.
Sales and Marketing Expenses
Our sales and marketing expenses decreased by $1,208, or 16%, to $6,363 for the three months ended September 30, 2023, compared to $7,571 for the three months ended September 30, 2022, and decreased by $7,240, or 27.4%, to $19,163 for the nine months ended September 30, 2023, compared to $26,403 for the nine months ended September 30, 2022. The decrease in sales and marketing expenses for the three months ended September 30, 2023 compared to the three months ended September 30, 2022, was mainly due to decreases in our payroll and related expenses.
The decrease in sales and marketing expenses for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022, was mainly due to the decrease in our digital marketing expenses and payroll and related expenses. Our sales and marketing expenses, excluding stock-based compensation and depreciation, for the three and nine months ended September 30, 2023 were $4,445 and $13,484 compared to $5,570 and $20,966 for the three and nine months ended September 30, 2022, a decrease of $1,125 and increase of $7,482 respectively.
Sales and marketing expenses consist mainly of employees’ salaries and related overhead costs, online marketing campaigns of our service offering, trade show expenses, customer support expenses and marketing consultants, marketing expenses and subcontractors.
General and Administrative Expenses
Our general and administrative expenses increased by $129, or 3.2%, to $4,128 for the three months ended September 30, 2023, compared to $3,999 for the three months ended September 30, 2022, and decreased by $842, or 6.3% to $12,611 for the nine months ended September 30, 2023, compared to $13,453 for the nine months ended September 30, 2022. The increase in general and administrative expenses for the three months ended September 30, 2023, compared to the three months ended September 30, 2022, was due to an increase in stock-based compensation and legal fees. The decrease in general and administrative expenses for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, was mainly due to a decrease in acquisition and restructuring costs expenses, and other consulting expenses during the nine months ended September 30, 2023. Our general and administrative expenses, excluding stock-based compensation, depreciation, acquisition-related costs and earn-out remeasurement for the three and nine months ended September 30, 2023, were $2,053 and $6,521 compared to $2,178 and $7,107 for the three and nine months ended September 30, 2022, a decrease of $125 and $586, respectively.
Our general and administrative expenses consist mainly of employees’ salaries and related overhead costs, directors’ fees, legal and accounting fees, patent registration, expenses related to investor relations, as well as our office rent and related expenses.
Financial Expenses, net
Our financial expenses, net for the three months ended September 30, 2023, were $186, representing a decrease of $873, compared to financial expenses of $1,059 for the three months ended September 30, 2022. Our financial expenses, net for the nine months ended September 30, 2023, were $3,168, representing an increase of $1,393, compared to financial expenses of $1,775 for the nine months ended September 30, 2022. The decrease in our financial expenses for the three months ended September 30, 2023 compared to the three months ended September 30, 2022, was mainly due to the increase in interest income and an income from the reduction of the revaluation of the long-term loan and the warrant liability relating to the loan provided by Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P., collectively as lenders (the “Avenue Lenders”). The increase in our financial expenses for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 was mainly due to expenses, related to the Company’s refinancing of its former $25,000 credit facility obtained on June 9, 2022 with a new $30,000 credit facility, interest expense, debt issuance costs and the revaluation of the long-term loan and the warrant liability relating to the loan previously provided by OrbiMed Royalty and Credit Opportunities III, LP (“Orbimed”).
Financial expenses, net primarily consists of credit facility interest expense, interest income from cash balances, the revaluation of short-term investments, bank charges, lease liability and foreign currency translation differences.
Net loss
Net loss increased by $100, or 0.6%, to $15,732 for the three months ended September 30, 2023, compared to a net loss of $15,632 for the three months ended September 30, 2022, and decreased by $4,434, or 8.9%, to $45,142 for the nine months ended September 30, 2023, compared to a net loss of $49,576 for the nine months ended September 30, 2022.
The decrease in net loss for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, was mainly due to the decrease in our operating expenses.
The factors described above resulted in net loss attributable to stockholders for the three and nine months ended September 30, 2023, amounted to $16,904 and $48,005, respectively, compared to net loss attributable to stockholders of $16,126 and $50,954 for the three and nine months ended September 30, 2022.
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented in accordance with “U.S. GAAP” within this Quarterly Report on Form 10-Q, management provides certain non-GAAP financial measures (“NGFM”) of the Company’s financial results, including such amounts captioned: “net loss before interest, taxes, depreciation, and amortization” or “EBITDA”, and “Non-GAAP Adjusted Loss”, as presented herein below. Importantly, we note the NGFM measures captioned “EBITDA” and “Non-GAAP Adjusted Loss” are not recognized terms under U.S. GAAP, and as such, they are not a substitute for, considered superior to, considered separately from, nor as an alternative to, U.S. GAAP and /or the most directly comparable U.S. GAAP financial measures.
Such NGFM are presented with the intent of providing greater transparency of information used by us in our financial performance analysis and operational decision-making. Additionally, we believe these NGFM provide meaningful information to assist investors, shareholders, and other readers of our unaudited condensed consolidated financial statements, in making comparisons to our historical financial results, and analyzing the underlying financial results of our operations. The NGFM are provided to enhance readers’ overall understanding of our current financial results and to provide further information to enhance the comparability of results between the current year period and the prior year period.
We believe the NGFM provide useful information by isolating certain expenses, gains, and losses, which are not necessarily indicative of our operating financial results and business outlook. In this regard, the presentation of the NGFM herein below, is to help the reader of our unaudited condensed consolidated financial statements to understand the effects of the non-cash impact on our (U.S. GAAP) unaudited condensed consolidated statement of operations of the revaluation of the warrants and the expense related to stock-based compensation, each as discussed herein above.
A reconciliation to the most directly comparable U.S. GAAP measure to NGFM, as discussed above, is as follows:
(in thousands)
| Net Loss Reconciliation | | Three Months Ended September 30, 2023 | | 2022 | | $ Change |
|---|---|---|---|---|---|---|
| Net loss - as reported | | $(15,732) | | $(15,632) | | $(100) |
| | | | | | | |
| Adjustments | | | | | ||
| Depreciation expense | | 99 | | 89 | | 10 |
| Amortization of acquired technology and brand | | 1,137 | | 1,136 | | 1 |
| Other financial expenses, net | | 186 | | 1,059 | | (873) |
| | | | | | | |
| EBITDA | | (14,310) | | (13,348) | | (962) |
| | | | | | | |
| Earn-out remeasurement | | — | | 6 | | (6) |
| Stock-based compensation expenses | | 5,159 | | 4,926 | | 233 |
| | | | | | | |
| Non-GAAP adjusted loss | | $(9,151) | | $(8,416) | | $(735) |
(in thousands)
| Net Loss Reconciliation | | Nine Months Ended September 30, 2023 | | 2022 | | $ Change |
|---|---|---|---|---|---|---|
| Net loss - as reported | | $(45,142) | | $(49,576) | | $4,434 |
| | | | | | | |
| Adjustments | | | | |||
| Depreciation expense | | 290 | | 243 | | 47 |
| Amortization of acquired technology and brand | | 3,375 | | 3,224 | | 151 |
| Other financial expenses, net | | 3,168 | | 1,775 | | 1,393 |
| Income tax | | — | | 1 | | (1) |
| | | | | | | |
| EBITDA | | (38,309) | | (44,333) | | 6,024 |
| | | | | | | |
| Earn-out remeasurement | | — | | 945 | | (945) |
| Stock-based compensation expenses | | 15,307 | | 13,898 | | 1,409 |
| | | | | | | |
| Non-GAAP adjusted loss | | $(23,002) | | $(29,490) | | $6,488 |
Liquidity and Capital Resources (amounts in thousands except for share and share amounts)
As of September 30, 2023, we had approximately $43,878 in cash and cash equivalents compared to $49,357 on December 31, 2022.
We have experienced cumulative losses of $333,855 since inception (August 11, 2011) through September 30, 2023, and have a stockholders’ equity of $68,035 as of September 30, 2023. In addition, we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover our operating costs and expect to continue to generate losses for the foreseeable future. However, we believe that our sources of liquidity and capital resources will be sufficient to meet our business needs for at least the next twelve months.
Since inception, we have financed our operations primarily through private placements and public offerings of our common stock and warrants to purchase shares of our common stock, receiving aggregate net proceeds totaling $244,392 and a credit facility of $25,564 as of September 30, 2023.
On February 28, 2022, we entered into a securities purchase agreement with institutional investors, pursuant to which we agreed to issue and sell to the investors in a registered direct offering priced at-the-market under Nasdaq rules an aggregate of 4,674,454 shares of our common stock, par value $0.0001 per share, and pre-funded warrants to purchase an aggregate of 667,559 shares of our common stock. Each share was sold at an offering price of $7.49 per share, and each pre-funded warrant was sold at an offering price of $7.4899, for aggregate gross proceeds of approximately $40 million before deducting the offering expenses. In addition, the investors have executed lock up agreements agreeing to a lock up period of three days.
On October 22, 2021, we entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), as agent, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $50 million from time to time through Cowen. For the nine months ended September 30, 2023, the Company received net proceeds of $1,614 from the sale of 408,043 shares of the Company’s common stock. As of September 30, 2023, there was $47,971 in remaining funds available under the Sales Agreement.
On February 1, 2021, we entered into securities purchase agreements with institutional accredited investors relating to an offering with respect to the sale of an aggregate of 3,278,688 shares of common stock, at a purchase price of $21.35 per share. The aggregate gross proceeds were approximately $70,000.
On May 1, 2023, we entered into securities purchase agreements with accredited investors relating to an offering and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock, an aggregate of 7,946 shares of
Series B-1 Preferred Stock, and an aggregate of 150 shares of Series B-2 Preferred Stock, at a purchase price of $1,000 for each share of Preferred Stock. Certain of our executive officers and directors purchased shares of Series B-2 Preferred Stock in the offering. On May 5, 2023, we entered into securities purchase agreements with accredited investors, relating to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock, at a purchase price of $1,000 for each share of Preferred Stock. As a result of the sale of the Preferred Stock, the aggregate gross proceeds to us from the offering are approximately $15.4 million.
On May 1, 2023, we entered into a Loan and Security Agreement, and Supplement thereto (the “LSA”), by and between the us and our subsidiary, PsyInnovations Inc. (“PsyInnovations”), collectively as the borrowers (the “Borrowers”) and the Avenue Lenders. The LSA provides for a four-year secured credit facility in an aggregate principal amount of up to $40 million, of which $30 million was made available on the closing date (the “Initial Tranche”) and up to $10 million may be made available on the later of July 1, 2023 or the date the Avenue Lenders approve the issuance of the Discretionary Tranche. On May 1, 2023, we closed on the Initial Tranche, less certain fees and expenses payable to or on behalf of the Avenue Lenders. As a result of the execution of the LSA and the funding of the Initial Tranche, the Company satisfied its prior Credit Agreement it previously executed with OrbiMed, on June 9, 2022 and terminated the Credit Agreement with Orbimed.
Management believes that the proceeds from the prior private placements and the Avenue Loan Facility and the funds we may draw down from the Sales Agreement, combined with our cash on hand and short-term investments are sufficient to meet our obligations as they come due for at least a period of twelve months from the date of the issuance of these unaudited condensed consolidated financial statements. As a result, we have resolved to remove the going concern note from our financial statements. There are no assurances, however, that we will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of our product offerings.
As such, we have a significant present need for capital. If we are unable to scale up our commercial launch of our products or meet our commercial sales targets (or if we are unable to generate any revenue at all), and if we are unable to obtain additional capital resources in the near term, we may be unable to continue activities absent material alterations in our business plans and our business might fail.
Additionally, readers are advised that available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. Should this occur, we will need to seek additional capital earlier than anticipated in order to fund (1) further development and, if needed (2) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch Dario, Dario Engage and Dario Intelligence, (3) expenses which will be required in order to expand manufacturing of our products, (4) sales and marketing efforts and (5) general working capital. Such funding may be unavailable to us on acceptable terms, or at all. Our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead to the failure of our company. This would particularly be the case if we are unable to commercially distribute our products and services in the jurisdictions and in the timeframes we expect.
Cash Flows (dollar amounts in thousands)
The following table sets forth selected cash flow information for the periods indicated:
| | | September 30, 2023 $ | | 2022 $ |
|---|---|---|---|---|
| Cash used in operating activities: | | (23,038) | (39,904) | |
| Cash used in investing activities: | | (464) | (514) | |
| Cash provided by financing activities: | | 18,253 | 61,675 | |
| | | (5,249) | | 21,257 |
Net cash used in operating activities
Net cash used in operating activities was $23,038 for the nine months ended September 30, 2023, a decrease of 42.3% compared to $39,904 used in operations for the same period in 2022. Cash used in operations decreased mainly due to the decrease in our net loss, decrease in trade receivables, inventories, and trade payables.
Net cash used in investing activities
Net cash used in investing activities was $464 for the nine months ended September 30, 2023 compared to $514 net cash used in investing activities during the same period in 2022. The decrease is a result of the decrease in our intangible assets purchased, and property and equipment purchased in the nine months ended September 30, 2023, compared to the same period in 2022.
Net cash provided from financing activities
Net cash derived from financing activities was $18,253 for the nine months ended September 30, 2023, compared to $61,675 net cash provided by financing activities during the same period in 2022. The decrease results from the decrease in the proceeds from the issuance of preferred shares in the nine months ended September 30, 2023 compared to the proceeds from the issuance of common stock and prefunded warrants in the nine months ended September 30, 2022, and from the reduction in the amounts borrowed in the first nine months of 2023 compared to the first nine months of 2022.
Controls and procedures
As filed, 2,722 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”), conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a–15(e) and 15d–15(e) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act“, the term “disclosure controls and procedures” means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including the Certifying Officers, to allow timely decisions regarding required disclosures.
Based on their evaluation, the Certifying Officers concluded that, as of September 30, 2023, our disclosure controls and procedures were designed at a reasonable assurance level and were therefore effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on the Effectiveness of Internal Controls
Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.
Risk factors
As filed, 11,232 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect our business, financial condition, or future results.
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, except as noted below.
Currently, our revenues are concentrated with two major customers, Sanofi, and a national health plan, and our revenues may decrease significantly if we were to lose our major customers.
Due to our limited operating history, we have a limited customer base and have depended on a major customer, Sanofi, for a significant portion of our revenue. On February 8, 2022, we entered into an exclusive preferred partner, co-promotion, development collaboration and license agreement for a term of five (5) years (the “Exclusive Agreement”) with Sanofi. Pursuant to the Exclusive Agreement, we will provide a license to access and use certain Company data. As of September 30, 2023, our major customer accounted for 77.5% of our accounts receivable balance and, for the three- and nine-month periods ended September 30, 2023, Sanofi accounted for 5.7% and 32.9%, respectively, of our revenue. If Sanofi were to terminate the Exclusive Agreement, or if we fail to adequately perform under the Exclusive Agreement, and if we are unable to diversify our customer base, our revenue could decline, and our results of operations could be adversely affected.
Our principal executive offices and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them.
Our executive offices and corporate headquarters are located in Israel. In addition, most of our officers are residents of Israel. Accordingly, political, economic and military and security conditions in Israel and the surrounding region may directly affect our business. Any conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could adversely affect our operations. Ongoing and revived hostilities in the Middle East or other Israeli political or economic factors, could harm our operations.
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.
The intensity and duration of Israel’s current war against Hamas is difficult to predict, as are such war’s economic implications on the Company’s business and operations and on Israel's economy in general. These events may be intertwined with wider macroeconomic indications of a deterioration of Israel’s economic standing, which may have a material adverse effect on the Company and its ability to effectively conduct some of its operations.
In connection with the Israeli security cabinet’s declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service. Certain of our employees and consultants (and their spouses or partners) in Israel have been called, and additional employees (or their spouses or partners) may be called, for service in the current or future wars or other armed conflicts with Hamas, and such persons may be absent for an extended period of time. As a result, our operations in Israel may be disrupted by such absences, which disruption may materially and adversely affect our business, prospects, financial condition and results of operations.
Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon has also launched missile, rocket and shooting attacks against Israeli military sites, troops, and Israeli towns in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on sites belonging to Hezbollah in southern Lebanon. It is possible that other terrorist organizations, including Palestinian military organizations in the West Bank, as well as other hostile countries, such as Iran, will join the hostilities. Such hostilities may include terror and missile attacks. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.
Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which could also adversely impact our business.
Prior to the Hamas attack in October 2023, the Israeli government pursued extensive changes to Israel’s judicial system. In response to the foregoing developments, individuals, organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact the business environment in Israel including due to reluctance of foreign investors to invest or transact business in Israel as well as to increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in securities markets, and other changes in macroeconomic conditions. The risk of such negative developments has increased in light of the recent Hamas attacks and the war against Hamas declared by Israel, regardless of the proposed changes to the judicial system and the related debate. To the extent that any of these negative developments do occur, they may have an adverse effect on our business, our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.
The market price of our common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our control.
The market price of our common stock has fluctuated, and may continue to fluctuate, widely, due to many factors, some of which may be beyond our control. These factors include, without limitation:
- “short squeezes”;
- comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media;
- large stockholders exiting their position in our securities or an increase or decrease in the short interest in our securities;
- actual or anticipated fluctuations in our financial and operating results;
- risks and uncertainties associated with the ongoing COVID-19 pandemic;
- changes in foreign currency exchange rates;
- the commencement, enrollment or results of our planned or future clinical trials of our product candidates or those of our competitors;
- the success of competitive drugs or therapies;
- regulatory or legal developments in the United States and other countries;
- the success of competitive products or technologies;
- developments or disputes concerning patent applications, issued patents or other proprietary rights;
- the recruitment or departure of key personnel;
- the level of expenses related to our product candidates or clinical development programs;
- litigation matters, including amounts which may or may not be recoverable pursuant to our officer and director insurance policies, regulatory actions affecting the Company and the outcome thereof;
- the results of our efforts to discover, develop, acquire or in-license additional product candidates;
- actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
- disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
- significant lawsuits, including patent or stockholder litigation;
- variations in our financial results or those of companies that are perceived to be similar to us;
- market conditions in our market sector;
- general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad; and
- investors’ general perception of us and our business.
Stock markets in general and our stock price in particular have recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies and our company. For example, the closing sale prices of our Common Stock from January 1, 2023 through October 27, 2023 ranged from a high of $6.22 per share (on January 17, 2023) to a low of $1.30 per share (on October 27, 2023). During that time, we have not experienced any material changes in our financial condition or results of operations that would explain such price volatility or trading volume; however, we have sold equity which was dilutive to existing stockholders. These broad market fluctuations may adversely affect the trading price of our securities. Additionally, these and other external factors have caused and may continue to cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent our stockholders from readily selling their shares of our common stock and may otherwise negatively affect the liquidity of our common stock.
In addition, if the stock price of our common stock continues to trade at its current level, it may imply as a negative indicator of the valuation of our intangible assets and our goodwill, which could result in an impairment for these assets.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $3.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $16.7m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $2.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-01-01 to 2023-09-30 | $10.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-07-01 to 2023-09-30 | $610.0k | us-gaap:GrossProfit |
| Gross profit | 9 months2023-01-01 to 2023-09-30 | $5.9m | us-gaap:GrossProfit |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $16.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$15.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | −$42.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$15.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$45.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | $0.49 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | $1.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | $0.49 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | $1.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 28,815,604 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 28,195,216 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | −$23.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $501.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-09-30 | $43.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $56.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $106.5m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $8.1m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-09-30 | $29.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-09-30 | $68.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-017301. Last ingested by Listed: Nov 14, 2026, 22:37 ET. Listed shows no prices and gives no investment advice.